Email this article Moscow experience of using etanercept biosimilar in patients with immune-inflammatory rheumatic diseases
- Authors: Zagrebneva A.I.1,2, Simonova E.N.1,3, Mezenova Т.V.1,4,5, Burmistrova N.B.1, Gavrikova Y.A.1,4, Dolgov V.V.1,4, Morozova E.O.1, Kodzeva Z.M.1, Sapogina K.S.6, Fomina A.A.2
-
Affiliations:
- City Clinical Hospital No. 52 of the Moscow Health Department
- Russian National Research Medical University named after N.I. Pirogov
- Peoples’ Friendship University of Russia
- Research Institute of Health Organization and Medical Management of the Moscow Health Department
- Russian Medical Academy continuing Professional Education
- National Research University “Higher School of Economics”
- Issue: Vol 14, No 4 (2022)
- Pages: 83-92
- Section: Original research
- URL: https://journals.eco-vector.com/vszgmu/article/view/116731
- DOI: https://doi.org/10.17816/mechnikov116731
- ID: 116731
Cite item
Open Access
Access granted
Abstract
The growing demand for biological disease-modifying antirheumatic drugs (bDMARDs) and their high cost put a heavy burden on the healthcare budget, thereby limiting the availability of treatment for patients. The introduction of bDMARDs’ biosimilars into clinical practice has made it possible to expand the availability of therapy for a larger number of patients. Our analysis of the use of the biosimilar etanercept Erelzi® in 103 patients with rheumatoid arthritis showed that the drug is highly effective in the treatment of rheumatoid arthritis. It can be used both in bionaive patients with the ineffectiveness of basic therapy, and in the case of medical switching from other biologics (including tumor necrosis factor alpha inhibitors (iTNF)) and targeted synthetic basic anti-inflammatory drugs (tsDMARDs), as well as when non-medical switching is necessary. The biosimilar of etanercept Erelzi® has optimal cost of treatment course and the lowest cost-effectiveness value, which means that its use will not affect the budget and will make highly effective therapy available to more patients.
Full Text
About the authors
Alena I. Zagrebneva
City Clinical Hospital No. 52 of the Moscow Health Department; Russian National Research Medical University named after N.I. Pirogov
Email: alrheumo@mail.ru
ORCID iD: 0000-0002-3235-1425
MD, Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowElena N. Simonova
City Clinical Hospital No. 52 of the Moscow Health Department; Peoples’ Friendship University of Russia
Email: 4130524@mail.ru
ORCID iD: 0000-0002-8372-6995
MD
Russian Federation, Moscow; MoscowТatiana V. Mezenova
City Clinical Hospital No. 52 of the Moscow Health Department; Research Institute of Health Organization and Medical Management of the Moscow Health Department; Russian Medical Academy continuing Professional Education
Email: tmezenova@mail.ru
ORCID iD: 0000-0002-8035-6669
SPIN-code: 8684-3579
MD, Cand. Sci. (Med.)
Russian Federation, Moscow; Moscow; MoscowNatalia B. Burmistrova
City Clinical Hospital No. 52 of the Moscow Health Department
Email: ANBurmistroba04@mail.ru
ORCID iD: 0000-0003-2366-0231
MD
Russian Federation, MoscowYuliya A. Gavrikova
City Clinical Hospital No. 52 of the Moscow Health Department; Research Institute of Health Organization and Medical Management of the Moscow Health Department
Author for correspondence.
Email: jgavrikovagkb52@gmail.com
ORCID iD: 0000-0001-8414-1545
MD
Russian Federation, Moscow; MoscowVladislav V. Dolgov
City Clinical Hospital No. 52 of the Moscow Health Department; Research Institute of Health Organization and Medical Management of the Moscow Health Department
Email: drdolgovvvv@gmail.com
ORCID iD: 0000-0001-8007-5499
MD
Russian Federation, Moscow; MoscowEvgeniya O. Morozova
City Clinical Hospital No. 52 of the Moscow Health Department
Email: morozova15950@yandex.ru
ORCID iD: 0000-0001-9406-2488
MD
Russian Federation, MoscowZhaneta M. Kodzeva
City Clinical Hospital No. 52 of the Moscow Health Department
Email: zhaneta996@mail.ru
ORCID iD: 0000-0001-7983-6115
MD
Russian Federation, MoscowKsenia S. Sapogina
National Research University “Higher School of Economics”
Email: ksenia.grossssmann@gmail.com
ORCID iD: 0000-0002-0727-5176
Russian Federation, Moscow
Anastasia A. Fomina
Russian National Research Medical University named after N.I. Pirogov
Email: fomina.med@gmail.com
ORCID iD: 0000-0002-4463-5847
Russian Federation, Moscow
References
- Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an International Task Force. Ann Rheum Dis. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919
- Federal’nyi zakon “Ob obrashchenii lekarstvennykh sredstv” ot 12.04.2010 No. 61-FZ. (In Russ.)
- Biosimilars in the EU: information guide for healthcare professionals [Internet]. EMA and European Commission (EC). 2019. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed: Feb 5, 2020.
- Weise M, Bielsky MC, de Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–5117. doi: 10.1182/blood-2012-04-425744
- Kay J. A ‘wind of change’ to biosimilars: the NOR-SWITCH trial and its extension. J Intern Med. 2019;285(6):693–695. doi: 10.1111/joim.12896
- Cohen HP, Lamanna WC, Schiestl M. Totality of Evidence and the Role of Clinical Studies. In: Biosimilars. Regulatory, Clinical, and Biopharmaceutical Development. Springer, Cham; 2018;34:601–628. doi: 10.1007/978-3-319-99680-6_22
- European Commission (EC). Information guide for patients: what do I need to know about biosimilar medicines 2017. Available from: https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/29112017-european-commission-launches-what-i-need-to-know-about-biosimilar-medicines-information-for-patients-in-23-eu-languages/. Accessed: Oct 24, 2017.
- McCamish M, Pakulski J, Sattler C, Woollett G. Toward interchangeable biologics. Clin Pharmacol Ther. 2015;97(3):215–217. doi: 10.1002/cpt.39
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–417. doi: 10.1038/clpt.2011.343
- Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83–91. doi: 10.1007/s40259-017-0210-0
- Macdonald JC, Hartman H, Jacobs IA. Regulatory considerations in oncologic biosimilar drug development. MAbs. 2015;7(4):653–661. doi: 10.1080/19420862.2015.1040973
- FDA’s overview of the regulatory guidance for the development and approval of biosimilar products in the US [Internet]. Available from: https://www.fda.gov/media/90496/download. Accessed: Feb 1, 2020.
- . Dedov II, Shestakova MV, Peterkova VA, et al. Russian association of endocrinologist draft recommendation on insulin biosimilars using. Diabetes mellitus. 2021;24(1):76–79. (In Russ.)
- Kulikov AYu, Serpik VG, Lila AM. Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. Modern Rheumatology Journal. 2022;16(3S):1–17. (In Russ.). doi: 10.14412/1996-7012-2022-2S-1-17
- Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21(1):130. doi: 10.1186/s13075-019-1907-x
- Griffits CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study compating the efficacy, safety and immunogencity of GP, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–938. doi: 10.1111/bjd.15152
- Jørgensen K, Olsen I, Goll G, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316. DOI: 1016/S0140-6736(17)30068-5
- Carballo N, Pérez García C, Grau S, et al. Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study. Front Pharmacol. 2022;13:980832. doi: 10.3389/fphar.2022.980832
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).